ImmuPharma firmly committed to Lupuzor ahead of managed access programme – 18th Sept 2018

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM), says lupus treatment Lupuzor will be entered into managed access programme to allow sufferers whose doctors recommend it.

Immupharma will get ‘real-world’ data from the MAP with up to 500 patients to receive the drug free of charge for two years.

That is more than twice the number of patients studied in all clinical trials for Lupuzor to date.